BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) and Brickell Biotech (NASDAQ:BBI – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Risk & Volatility
BioCryst Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Brickell Biotech has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.
This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Brickell Biotech, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioCryst Pharmaceuticals presently has a consensus price target of $18.36, indicating a potential upside of 103.14%. Brickell Biotech has a consensus price target of $2.00, indicating a potential upside of 1,464.95%. Given Brickell Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Brickell Biotech is more favorable than BioCryst Pharmaceuticals.
Earnings & Valuation
This table compares BioCryst Pharmaceuticals and Brickell Biotech’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$157.17 million||10.71||-$184.06 million||($1.07)||-8.48|
|Brickell Biotech||$400,000.00||38.15||-$39.47 million||($0.46)||-0.28|
Brickell Biotech has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Brickell Biotech, indicating that it is currently the more affordable of the two stocks.
This table compares BioCryst Pharmaceuticals and Brickell Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
63.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.0% of Brickell Biotech shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Brickell Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BioCryst Pharmaceuticals beats Brickell Biotech on 8 of the 14 factors compared between the two stocks.
About BioCryst Pharmaceuticals (Get Rating)
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
About Brickell Biotech (Get Rating)
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.